GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of ACRS
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Thursday for Aclaris Therapeutics stock after losing 0%
(Updated on Apr 18, 2024)

Buy candidate since Apr 17, 2024 PDF

No changes to the price of Aclaris Therapeutics stock on the last trading day (Thursday, 18th Apr 2024). During the last trading day the stock fluctuated 4.13% from a day low at $1.21 to a day high of $1.26. The price has been going up and down for this period, and there has been a 0% change for the last 2 weeks.

The stock is moving within a very wide and horizontal trend and further movements within this trend can be expected. Given the current horizontal trend, you can expect Aclaris Therapeutics stock with a 90% probability to be traded between $1.16 and $1.45 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the top. Stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

ACRS Signals & Forecast

Mostly positive signals in the chart today. The Aclaris Therapeutics stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down, there will be some support from the lines at $1.21 and $1.23. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Thursday, March 14, 2024, and so far it has risen 6.96%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume gained on the last day while the price remained unchanged. This is not a classical divergence, but the stock should be watched more closely at it may be a "turning point".

Support, Risk & Stop-loss for Aclaris Therapeutics stock

Aclaris Therapeutics finds support from accumulated volume at $1.21 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.0500 between high and low, or 4.13%. For the last week, the stock has had daily average volatility of 4.42%.

Our recommended stop-loss: $1.16 (-5.48%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 24 days ago.)

Trading Expectations (ACRS) For The Upcoming Trading Day Of Friday 19th

For the upcoming trading day on Friday, 19th we expect Aclaris Therapeutics to open at $1.23, and during the day (based on 14 day Average True Range), to move between $1.16 and $1.30, which gives a possible trading interval of +/-$0.0710 (+/-5.77%) up or down from last closing price. If Aclaris Therapeutics takes out the full calculated possible swing range there will be an estimated 11.54% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $1.25 (1.63%) than the support at $1.21 (1.63%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Aclaris Therapeutics stock A Buy?

Several short-term signals are positive and we conclude that the current level may hold a buying opportunity, as there is a fair chance for Aclaris Therapeutics stock to perform well in the short-term period.

Current score: 2.057 Buy Candidate Unchanged

Predicted Opening Price for Aclaris Therapeutics of Friday, April 19, 2024

Fair opening price April 19, 2024 Current price
$1.23 ( 0.271%) $1.23

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ACRS

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1.28 4.34 %
R2 1.26 2.78 %
R1 1.25 1.82 %
Current price: 1.23
Support S1 1.21 -1.28 %
S2 1.20 -2.24 %
S3 1.18 -3.79 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 1.28 4.07 %
R2 1.26 2.44 %
R1 1.25 1.63 %
Current price 1.23
Support S1 1.21 -1.63%
S2 1.20 -2.44%
S3 1.19 -3.25%

FAQ

What is the symbol for Aclaris Therapeutics Stock and on which exchange is it traded?
The symbol for Aclaris Therapeutics is ACRS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Aclaris Therapeutics Stock?
Several short-term signals are positive and we conclude that the current level may hold a buying opportunity, as there is a fair chance for Aclaris Therapeutics stock to perform well in the short-term period.

How to buy Aclaris Therapeutics Stock?
Aclaris Therapeutics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Aclaris Therapeutics Stock.

What's the current price of Aclaris Therapeutics Stock?
As of the end of day on the 2024-04-18, the price of an Aclaris Therapeutics (ACRS) share was $1.23.

What is the 52-week high and low for Aclaris Therapeutics Stock?
The 52-week high for Aclaris Therapeutics Stock is $11.12 and the 52-week low is $0.590.

What is the market capitalization of Aclaris Therapeutics Stock?
As of the 2024-04-18, the market capitalization of Aclaris Therapeutics is 87.238M.

When is the next earnings date for Aclaris Therapeutics?
The upcoming earnings date for Aclaris Therapeutics is May 13, 2024.
Click to get the best stock tips daily for free!

About Aclaris Therapeutics

Aclaris Therapeutics Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of... ACRS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT